Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply

Aliment Pharmacol Ther. 2020 Aug;52(4):753-754. doi: 10.1111/apt.15959.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Crohn Disease* / drug therapy
  • Humans
  • Tumor Necrosis Factor-alpha
  • Ustekinumab* / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Tumor Necrosis Factor-alpha
  • vedolizumab
  • Ustekinumab